IRWD — Ironwood Pharmaceuticals, Inc.

Is IRWD overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Drug Manufacturers - Specialty & Generic

Overbought As of November 17, 2026

Ironwood Pharmaceuticals, Inc. (IRWD) currently reads Overbought on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Drug Manufacturers - Specialty & Generic) last closed at $4.85.

See all overbought Healthcare stocks →

AI analysis

Ironwood Pharmaceuticals, Inc. (IRWD) is a small-cap specialty pharmaceutical company supported by recurring royalties from its gastrointestinal franchise and a modest early-to-mid-stage pipeline. The business benefits from baseline cash flow but remains sensitive to partner execution, clinical/regulatory outcomes, and capital markets for financing. Near-term upside is tied to successful pipeline readouts or attractive M&A interest from larger pharma, while downside stems from potential loss of exclusivity, financing dilution, or trial/regulatory setbacks. Given limited social/research visibility and sector flows that currently favor large-cap pharma, price action is likely to be driven by company-specific news and partner updates.

Key factors

  • Ongoing legacy revenue stream from the gastrointestinal franchise (royalties/licensing) provides baseline cash flow and reduces binary pipeline dependence.
  • Small-cap biotech profile with a relatively thin product portfolio — limited diversification increases sensitivity to single-product performance and partner decisions.
  • Early-to-mid-stage pipeline that could deliver near-term clinical or licensing catalysts, which would materially re-rate the equity if positive.
  • Broader market environment favoring large-cap pharma and defensive healthcare may limit multiple expansion for smaller specialty biopharma names, though M&A appetite among large pharmas could create strategic value.
  • Current market backdrop (risk-on but earnings-driven) suggests idiosyncratic company news and partner updates will drive short-term moves rather than macro shocks.

Risks

  • Commercial/partner execution risk: outcomes or strategic changes from commercial partners could materially affect revenue.
  • Clinical and regulatory risk: pipeline programs are early-to-mid-stage and subject to trial setbacks or regulatory delays.
  • Financing and dilution risk: limited diversification and modest free cash flow raise the possibility of equity or convertible financing, which would dilute existing shareholders.
  • Loss of exclusivity or generic competition for legacy products could reduce royalty streams faster than anticipated.
  • Low visibility in social and sell-side sentiment and limited coverage can exacerbate volatility and reduce liquidity.

See today's live rating, score and targets

Members see the live hourly rating for IRWD — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.